AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16364231 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm timings in FCWS at different driving speeds (40, 60, 70 mile/h) and time headways (1.7 and 2.2 s)
Number of subjects: 0
Study 16364231 — intervention group
Group type: EXPERIMENTAL
Intervention: Late alarms presented after braking actions initiated
Number of subjects: 0
Study 15804075 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) pretreatment
Number of subjects: 16
Study 15804075 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 16
Study 11041396 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 (2 mg/kg over 30 min followed by 2 mg/kg over 24 h)
Number of subjects: 393
Study 11041396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 mg/mL human albumin solution)
Number of subjects: 393
Study 11041396 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 393
Study 11041396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 8769511 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) oral rinse
Number of subjects: 353
Study 8335049 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of Epirubicin immediately after TUR
Number of subjects: 501
Study 8335049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold forceps biopsy and fulguration
Number of subjects: 501
Study 8335049 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection by urologist
Number of subjects: 501
Study 2868163 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 0
Study 29094806 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based approach for the diagnosis and management of FGIDs (ADAM-FGID)
Number of subjects: 0
Study 29094806 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 27090649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) high assist
Number of subjects: 23
Study 27090649 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) high assist
Number of subjects: 23
Study 27090649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV) targeting large V T (15 mL × kg(‐1))
Number of subjects: 23
Study 27090649 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) low assist
Number of subjects: 23
Study 27090649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) low assist
Number of subjects: 23
Study 24966672 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 1266
Study 24966672 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 1266
Study 24966672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1266
Study 22142341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-coseasonal SLIT
Number of subjects: 60
Study 22142341 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SLIT
Number of subjects: 60
Study 22142341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19717399 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study 19717399 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 0
Study 19717399 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors + methotrexate (MTX)
Number of subjects: 0
Study 19717399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19099008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs)
Number of subjects: 5822
Study 15886247 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 83
Study 15886247 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2550 mg/d
Number of subjects: 83
Study 15886247 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 83
Study 12957432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions per week, 60 minutes each, for 4 months)
Number of subjects: 16
Study 12957432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 16
Study 12957432 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 16
Study 12957432 — intervention group
Group type: COMPARATOR
Intervention: Trained normal controls
Number of subjects: 16
Study 11007078 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT) performed in the operating room by a head and neck surgeon (group 1)
Number of subjects: 311
Study 11007078 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard operative tracheostomy performed by the same surgeon (group 2)
Number of subjects: 311
Study 11007078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside PDT by critical care physicians (group 3)
Number of subjects: 311
Study 8874243 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine base (38.5 +/- 2.3 mg)
Number of subjects: 14
Study 8874243 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cocaine HCl (30.0 +/- 2.0 mg)
Number of subjects: 14
Study 8874243 — intervention group
Group type: COMPARATOR
Intervention: Smoked placebo (2.3 +/- 0.9 mg cocaine base)
Number of subjects: 14
Study 8874243 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline solution placebo
Number of subjects: 14
Study 1509861 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin b.i.d. for 5 days
Number of subjects: 132
Study 1509861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 6714054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 10
Study 6714054 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine and antacid suspension
Number of subjects: 10
Study 30919249 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Amlodipine SPC (3.5/2.5 mg to 14/10 mg)
Number of subjects: 1617
Study 30919249 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (150 mg to 300/25 mg)
Number of subjects: 1617
Study 29301123 — intervention group
Group type: COMPARATOR
Intervention: 1,426 ppm F (control)
Number of subjects: 62
Study 29301123 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn-A (0.3% ZnCl2, 1,426 ppm F)
Number of subjects: 62
Study 29301123 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn-B (as Zn-A, with high-foaming surfactants)
Number of subjects: 62
Study 27420976 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Da Chengqi granules
Number of subjects: 77
Study 23999996 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for minimum movement
Number of subjects: 9
Study 23999996 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for maximum movement
Number of subjects: 9
Study 23999996 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for post-fatigue maximum movement
Number of subjects: 9
Study 23999996 — intervention group
Group type: COMPARATOR
Intervention: Post-fatigue maximum movement compared to maximum movement
Number of subjects: 9
Study 22562516 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in Northern Ireland aged 12 to 13 years
Number of subjects: 0
Study 22562516 — intervention group
Group type: COMPARATOR
Intervention: Children in Sydney aged 12 to 13 years
Number of subjects: 0
Study 22562516 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in Northern Ireland (both ages)
Number of subjects: 0
Study 19937046 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH486757 100 mg
Number of subjects: 91
Study 19937046 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 30 mg
Number of subjects: 91
Study 19937046 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 91
Study 18327795 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscectomy patients
Number of subjects: 105
Study 18327795 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 105
Study 15825069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 1 g/day
Number of subjects: 80
Study 15825069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12442930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% 30 mL (+epinephrine 5 microg mL(‐1))
Number of subjects: 40
Study 12442930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% 15 mL (+epinephrine 5 microg mL(‐1))
Number of subjects: 40
Study 10359905 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat's milk (GM)
Number of subjects: 26
Study 10359905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk (CM)
Number of subjects: 26
Study 10359905 — intervention group
Group type: COMPARATOR
Intervention: Soy formula (Isomil, Abbott, Italy)
Number of subjects: 26
Study 10359905 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP inhibition tests with CM or GM
Number of subjects: 26
Study 10359905 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblotting inhibition assays with CM and GM
Number of subjects: 26
Study 7718316 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 318
Study 7718316 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen
Number of subjects: 318
Study 7718316 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen in patients with skeletal metastases
Number of subjects: 318
Study 1850870 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy with interdisciplinary communication among therapists (surgeon, radiotherapist, oncologist) and pathologist.
Number of subjects: 0
Study 1850870 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy under unfavorable prerequisites for cosmetically satisfactory results.
Number of subjects: 0
Study 6345013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 1000 mg
Number of subjects: 147
Study 6345013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 750 mg
Number of subjects: 147
Study 6345013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 500 mg
Number of subjects: 147
Study 30628088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin (500 mg for 3 days)
Number of subjects: 38
Study 30628088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive amoxicillin plus metronidazole (500 mg AMX plus 400 mg MTZ three times per day for 7 days)
Number of subjects: 38
Study 30628088 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 38
Study 28110355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrations-Dive (VD) group
Number of subjects: 26
Study 28110355 — intervention group
Group type: COMPARATOR
Intervention: Diving (D) group (control)
Number of subjects: 26
Study 28110355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (V) protocol group
Number of subjects: 26
Study 26342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to increase HIV testing rates
Number of subjects: 0
Study 26342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to increase ART engagement
Number of subjects: 0
Study 26342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to optimize ART retention
Number of subjects: 0
Study 23446085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 36
Study 23446085 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 36
Study 22969203 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (PAM): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid for 10 days
Number of subjects: 107
Study 22969203 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PAMB): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid, bismuth subcitrate 240 mg bid for 10 days
Number of subjects: 107
Study 19118805 — intervention group
Group type: EXPERIMENTAL
Intervention: Relinquishing three activities
Number of subjects: 206
Study 19118805 — intervention group
Group type: EXPERIMENTAL
Intervention: Relinquishing five activities
Number of subjects: 206
Study 18001671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment for smoking cessation without nicotine replacement
Number of subjects: 74
Study 15005584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with vein decompression (Group 1)
Number of subjects: 35
Study 15005584 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy without vein decompression (Group 2)
Number of subjects: 35
Study 12577415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) plus Xiaoliu Pingyi Mixture (XLPYM)
Number of subjects: 96
Study 12577415 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 96
Study 9529460 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 255
Study 9529460 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study 7984290 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatosetron (13 mg or 0.19 mg/kg)
Number of subjects: 0
Study 7984290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2644533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin) administered on days 1 and 8, starting within 36 hours after mastectomy
Number of subjects: 1275
Study 2644533 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1275
Study 781229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 21
Study 781229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31418411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa + Probiotics
Number of subjects: 40
Study 31418411 — intervention group
Group type: COMPARATOR
Intervention: Pentasa
Number of subjects: 40
Study 28356246 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140
Study 28356246 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140
Study 25285681 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 55
Study 25285681 — intervention group
Group type: COMPARATOR
Intervention: abobotulinumtoxinA
Number of subjects: 55
Study 23939842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal and laparoscopy
Number of subjects: 74
Study 23939842 — intervention group
Group type: COMPARATOR
Intervention: Standard reversal
Number of subjects: 74
Study 22075345 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic epidurally (Group A)
Number of subjects: 17
Study 22075345 — intervention group
Group type: COMPARATOR
Intervention: M relaxant (Group B)
Number of subjects: 17
Study 19938102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at a standard dose of 2g per kg body weight
Number of subjects: 174
Study 17305940 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (S)
Number of subjects: 8
Study 17305940 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study 15170013 — intervention group
Group type: EXPERIMENTAL
Intervention: COL-1492 vaginal gel containing 52.5 mg nonoxynol-9
Number of subjects: 0
Study 15170013 — intervention group
Group type: COMPARATOR
Intervention: Safer sex counselling and male condoms (provided at each visit)
Number of subjects: 0
Study 11426000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (50 years or younger)
Number of subjects: 66
Study 11426000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 women
Number of subjects: 66
Study 11426000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 men
Number of subjects: 66
Study 11426000 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (older than 50 years with compression fracture)
Number of subjects: 66
Study 10052024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 94
Study 10052024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml saline intravenous)
Number of subjects: 94
Study 7844226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ménézo B2 medium
Number of subjects: 0
Study 7844226 — intervention group
Group type: COMPARATOR
Intervention: Earle's medium
Number of subjects: 0
Study 3142396 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (MD) 500 mg/bid, optimal dosage up to 1500 mg/bid
Number of subjects: 63
Study 3142396 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (LAB) 400 mg/bid, optimal dosage up to 1200 mg/bid
Number of subjects: 63
Study 3142396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (ACE) 400 mg/bid, optimal dosage up to 1200 mg/bid
Number of subjects: 63
Study 3142396 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (MD)
Number of subjects: 63
Study 30088008 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-month family-based, community-centered program (n=304 pairs) consisting of 12 weekly skills-building sessions, followed by monthly coaching calls for 9 months, and a 24-month sustainability phase.
Number of subjects: 610
Study 30088008 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-month family-based, community-centered program (n=304 pairs)
Number of subjects: 610
Study 30088008 — intervention group
Group type: COMPARATOR
Intervention: School-readiness control program (n=306 pairs) consisting of 6 sessions delivered over 36 months.
Number of subjects: 610
Study 30088008 — intervention group
Group type: COMPARATOR
Intervention: School-readiness control program (n=306 pairs)
Number of subjects: 610
Study 27623957 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 1200 mg plus a probiotic blend (Lactobacillus salivarius, Lactobacillus acidophilus, Bifidobacterium bifidus strain BGN4)
Number of subjects: 60
Study 27623957 — intervention group
Group type: COMPARATOR
Intervention: mesalazine 1200 mg
Number of subjects: 60
Study 24587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful external cephalic version (ECV)
Number of subjects: 67
Study 24587759 — intervention group
Group type: COMPARATOR
Intervention: Control group (cephalic singletons)
Number of subjects: 67
Study 24587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous flexed breeches
Number of subjects: 67
Study 24587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index (AFI) of 13 or more
Number of subjects: 67
Study 22408273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 50
Study 22408273 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (NS)
Number of subjects: 50
Study 20929467 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity leg‐strengthening exercises
Number of subjects: 26
Study 20929467 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation and mental imagery (Control)
Number of subjects: 26
Study 18190669 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-ARM training (four one-to-one sessions)
Number of subjects: 231
Study 18190669 — intervention group
Group type: COMPARATOR
Intervention: ARM Express (single session)
Number of subjects: 231
Study 18190669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 231
Study 15707565 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Abortion (MA)
Number of subjects: 368
Study 15707565 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Abortion (SA)
Number of subjects: 368
Study 15707565 — intervention group
Group type: COMPARATOR
Intervention: Preference for abortion method
Number of subjects: 368
Study 11975427 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF-tube
Number of subjects: 0
Study 11975427 — intervention group
Group type: COMPARATOR
Intervention: TOF-Guard/TOF-Watch arm board
Number of subjects: 0
Study 10435394 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1 mg single oral dose)
Number of subjects: 9
Study 10435394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7587563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TAPP procedure
Number of subjects: 102
Study 7587563 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 102
Study 1835664 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 717
Study 1835664 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 717
Study 1835664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 7004559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter
Number of subjects: 40
Study 7004559 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 40
Study 31831080 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + training (app-based cognitive bias modification)
Number of subjects: 100
Study 31831080 — intervention group
Group type: COMPARATOR
Intervention: TAU (control group)
Number of subjects: 100
Study 29079563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen‐alone
Number of subjects: 1020
Study 29079563 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC=0
Number of subjects: 1020
Study 29079563 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC >0
Number of subjects: 1020
Study 29079563 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC >100
Number of subjects: 1020
Study 26488269 — intervention group
Group type: EXPERIMENTAL
Intervention: MeFirst intervention (individually tailored, online educational intervention)
Number of subjects: 661
Study 26488269 — intervention group
Group type: COMPARATOR
Intervention: Control (standard CDC information factsheet on HPV vaccine)
Number of subjects: 661